Compare Citius Pharmaceuticals Inc (CTXR) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Estee Lauder Companies Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Estee Lauder Companies Inc trades at $95.9 (market cap $34.17B). The key difference: Estee Lauder Companies Inc is far larger — about 2508.8× Citius Pharmaceuticals Inc's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Estee Lauder Companies Inc for 122 Days on average.
| CTXR | EL | |
|---|---|---|
Market Cap | $13.62M | $34.17B |
Volume | 132,438 | 3,921,497 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $119.61 |
52-Week Low | $0.48 | $67.23 |
Typical Hold Time | 16 Days | 122 Days |
Enterprise Value | $3.79M | $39.92B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Estée Lauder (EL) trades at $94.45, up 1.17% with a bullish technical signal from moving averages. The company shows mixed fundamentals with a high P/E ratio of 188.9 but strong gross margins of 75.5%. Recent earnings beats in Q4 2025 and Q1 2026 contrast with a net loss of $1.13B in 2025. Analyst consensus is positive with 47.8% buy ratings and a $103 price target. Recent developments include AI partnerships and leadership changes.
Outlook remains cautiously optimistic as the company navigates profitability challenges while investing in digital transformation. Key opportunities include margin recovery and AI-driven growth initiatives, balanced against competitive pressures and execution risks in the beauty sector. The stock offers potential upside to analyst targets if turnaround efforts succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
